Sleep Disorders Drug Development Pipeline Examined by GBI Research in Its In-Demand Report Available at MarketPublishers.com

19 Oct 2017 • by Natalie Aster

LONDON – Restless legs syndrome (RLS) is recognised as a neurologic disorder characterised by a distressing, irresistible need/urge to move the legs. The key risk factors for the development of RLS comprise kidney failure, low iron levels, Parkinson’s disease, rheumatoid arthritis, pregnancy and diabetes mellitus.

Nocturia, a.k.a. nocturnal polyuria, pertains to excessive urination during night time. This disorder becomes more common with age and may also result from the usage of diuretic substances, edema from heart failure, prescription drugs, prostate, insomnia.

Insomnia is known as a sleep disorder associated with difficulty in falling/staying asleep. The key symptoms of insomnia are anxiety, depression, irritability, difficulty to fall asleep at night and waking up during night time.

The size of therapeutic pipelines for these disorders ranges from 8 products for RLS and nocturia to 31 for insomnia. All these indications have a great diversity of molecular targets owing to various pathologies of the indications.

In-demand research report “Sleep Disorders Drug Development Pipeline Review, 2017” worked out by GBI Research gives a comprehensive assessment of the sleep disorders therapeutics pipeline. It reviews therapeutic options under development, provides data on the leading companies engaged in therapeutic development and also covers dormant and discounted projects. Furthermore, this study reviews the most prominent pharmaceutical approaches at different stages of pipeline, identifies the major R&D milestones, touches upon the most recent developments and discusses the hottest issues. Additionally, the report provides a short-term, all-round future outlook for the sleep disorders drug development pipeline.

Reasons to Purchase:

  • gain clear understanding of the sleep disorders drug pipeline;
  • become abreast of all products in therapeutic development for each indication;
  • learn about products under development;
  • delve into competitive environment and point out the most active players;
  • identify the key challenges and opportunities;
  • evaluate the composition of the sleep disorders drug pipeline in terms of molecular target, molecule type, mechanism of action and route of administration;
  • find out, how the sleep disorders drug pipeline is poised to develop in the years ahead;
  • etc.

For a full collection of the publisher’s research studies follow GBI Research page at MarketPublishers.com.

CONTACTS

The Market Publishers, Ltd.
Natalie Aster
Tel: +44 208 144 6009
Fax: +44 207 900 3970
ps@marketpublishers.com
MarketPublishers.com